Affimed

Affimed Forward P/E

Delisted

The Forward P/E Ratio of Affimed (AFMD) as of Nov 19, 2026 is -0.01. In the previous year, Forward P/E Ratio was -0.01 — a change of -18.82% (higher).

Forward P/E

-0.01

YoY

-18.82%

Last updated:

Forward P/E Ratio of Affimed is 2023 -0.01 . Forward P/E Ratio of Affimed was 2022 -0.01 . It decreases by -18.82% higher compared to the previous year.

The Affimed Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2016
-0.02 EUR
Jan 1, 2017
-0.02 EUR
Jan 1, 2018
-0.03 EUR
Jan 1, 2019
-0.02 EUR
Jan 1, 2020
-0.02 EUR
Jan 1, 2021
-0.01 EUR
Jan 1, 2022
-0.01 EUR
Jan 1, 2023
-0.01 EUR
The Affimed Forward P/E history
YEARForward P/EYoY
-0.01-18.82%
-0.01-33.12%
-0.01-28.09%
-0.02-21.76%
-0.02-39.82%
-0.03+55.17%
-0.02+6.59%
-0.02-37.18%
-0.03-98.72%
-2.44—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Affimed Stock analysis

What does Affimed do? Affimed NV develops targeted cancer immunotherapies focused on immuno-oncology, leveraging the immune system to combat tumor cells. The company's product pipeline includes AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma, AFM13 combined with adoptive NK cells or anti-PD-1, and AFM24 for advanced EGFR-expressing solid tumors. Affimed is conducting a registration-directed study for AFM13 and a Phase 1/2a study for AFM24, alongside preclinical candidates like AMF26 for multiple myeloma and AMF28/AMF32 for multiple tumor targets. The firm collaborates with Genentech to develop and commercialize certain product candidates for multiple cancers. Affimed generates revenue primarily through collaboration agreements, such as the partnership with Genentech, which covers development and commercialization of specific therapies. The company's primary customers are pharmaceutical and biotechnology firms seeking to expand their oncology portfolios, particularly those interested in immuno-oncology approaches. Affimed's target segments include patients with relapsed/refractory peripheral T-cell Lymphoma, advanced EGFR-expressing solid tumors, and multiple myeloma, as well as broader oncology markets for its preclinical candidates. The company's revenue streams are tied to milestone payments and potential royalties from partnered products, with Genentech being a key collaborator. Affimed's focus on immuno-oncology positions it to attract partnerships with major pharmaceutical players looking to enhance their cancer therapy offerings. Its clinical-stage products, such as AFM13 and AFM24, are in advanced development phases, making them attractive for strategic alliances that drive commercialization and revenue generation. Affimed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Affimed stock

Forward P/E Ratio of Affimed is -0.01 in 2023.

Forward P/E Ratio of Affimed changed from -0.01 to -0.01, representing a -18.82% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Affimed since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Affimed with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Affimed

All Key Metrics — Affimed